<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">COPD</journal-id><journal-id journal-id-type="publisher-id">lcpd</journal-id><journal-title>COPD</journal-title><issn pub-type="ppub">1541-2555</issn><issn pub-type="epub">1541-2563</issn><publisher><publisher-name>Informa Healthcare</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19353352</article-id><article-id pub-id-type="pmc">2645850</article-id><article-id pub-id-type="doi">10.1080/15412550802522783</article-id><article-categories><subj-group subj-group-type="heading"><subject>Perspectives</subject></subj-group></article-categories><title-group><article-title>Venous Admixture in COPD: Pathophysiology and Therapeutic Approaches</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cooper</surname><given-names>Christopher B.</given-names></name><xref ref-type="aff" rid="au1">1</xref><email>ccooper@mednet.ucla.edu</email></contrib><contrib contrib-type="author"><name><surname>Celli</surname><given-names>Bartolome</given-names></name><xref ref-type="aff" rid="au2">2</xref><email>bcelli@copdnet.org</email></contrib><aff id="au1"><sup>1</sup>David Geffen School of Medicine, University of California, Los Angeles, California, USA</aff><aff id="au2"><sup>2</sup>Caritas St Elizabeth's Medical Center, Tufts University, Boston, Massachusetts, USA</aff></contrib-group><author-notes><corresp>Correspondence to: Christopher B. Cooper, Professor of Medicine and Physiology, David Geffen School of Medicine, University of California, Los Angeles, 10833 Le Conte Avenue, 37-131 CHS, Los Angeles CA 90095-1690 phone: +1 310 825 4440 fax: +1 310 206 8211 email: <email>ccooper@mednet.ucla.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>1</month><year>2009</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2008</year></pub-date><volume>5</volume><issue>6</issue><fpage>376</fpage><lpage>381</lpage><permissions><copyright-statement>Copyright &#x000a9; 2008 Informa Healthcare USA, Inc.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><p>This is an open access article distributed under the <ext-link ext-link-type="uri" xlink:href="http://www.informaworld.com/mpp/uploads/iopenaccess_tcs.pdf">Supplemental Terms and Conditions for iOpenAccess articles published in Informa Healthcare journals</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>Chronic obstructive and interstitial lung diseases impair pulmonary gas exchange leading to wasted ventilation (alveolar dead space) and wasted perfusion (venous admixture). These two fundamental types of abnormality represent opposite ends of the spectrum of ventilation-perfusion mismatch with <mml:math id="M1"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> ratios of infinity and zero. Treatment approaches that improve airway function, reduce air trapping and hyperinflation have received much attention and might be successful at ameliorating the problems associated with high <mml:math id="M2"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math>. However, in patients with low <mml:math id="M3"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> abnormality in whom venous admixture leads to hypoxemia, there are few therapeutic options. Indeed, some patients are refractory to treatment with supplemental oxygen particularly during exercise. Theoretically these patients could benefit from an intervention that increased mixed venous oxygen content thereby ameliorating the deleterious effects of venous admixture. In this perspective article we discuss the mechanisms whereby venous admixture contributes to hypoxemia and reduced oxygen delivery to tissues. We explore methods which could potentially increase mixed venous oxygen content thus ameliorating the deleterious effects of venous admixture. One such intervention that warrants further investigation is the therapeutic creation of an arterio-venous fistula. Such an approach would be novel, simple and minimally invasive. There is reason to believe that complications would be minor leading to a favorable risk-benefit analysis. This approach to treatment could have significant impact for patients with COPD but should also benefit any patient with chronic hypoxemia that impairs exercise performance.</p></abstract><kwd-group><kwd>COPD</kwd><kwd>Gas Exchange</kwd><kwd>Venous Admixture</kwd></kwd-group></article-meta></front><body><sec><title>INTRODUCTION</title><p>Chronic pulmonary diseases, both obstructive and restrictive, impose mechanical constraints on pulmonary ventilation but also disrupt gas exchange through a variety of complex mechanisms (<xref ref-type="bibr" rid="b1">1</xref>). Pulmonary gas exchange is crucial for oxygen uptake and carbon dioxide elimination and must be adjusted to match the varying metabolic demands of the body (<xref ref-type="bibr" rid="b2">2</xref>).</p><p>Gas exchange relies upon efficient matching of ventilation with perfusion in the lungs (<xref ref-type="bibr" rid="b3">3</xref>). An ideal ventilation-perfusion (<mml:math id="M4"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math>) ratio exists with a numerical value of 0.8 when ventilation and perfusion are expressed in like units (e.g., L/min). <mml:math id="M5"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> can be considered for the respiratory system as a whole or in terms of many individual lung units each of which could be regarded conceptually as an alveolus and its pulmonary capillaries. An ideal lung would have a uniform distribution of <mml:math id="M6"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> with values close to 0.8. In reality this does not happen and a spectrum of <mml:math id="M7"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> exists from zero to infinity. In normal subjects, the main factor that affects <mml:math id="M8"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> is gravity resulting, in the upright posture, in a gradient from high values at the lung apices to low values at the lung bases.</p><p>In patients with chronic pulmonary disease it is the pathological destruction of the lung parenchyma that disrupts <mml:math id="M9"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> and since the pathology is often unevenly distributed throughout the lungs, the <mml:math id="M10"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> mismatch is said to be heterogeneous. Certain areas of the lung could be over-ventilated relative to perfusion. In these circumstances <mml:math id="M11"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> <italic>is high</italic> and a proportion of the ventilation can be considered as &#x0201c;wasted&#x0201d;. Areas of the lung that are ventilated but receive no perfusion have a <mml:math id="M12"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> ratio of infinity. Other areas of the lung could be under-ventilated relative to perfusion. In these circumstances <mml:math id="M13"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> <italic>is low</italic> and a proportion of the perfusion can be considered to be &#x0201c;wasted&#x0201d;. Areas of the lung that are perfused but receive no ventilation have a <mml:math id="M14"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> ratio of zero.</p><p>In summary, there are essentially two types of gas exchange abnormality&#x02014;high <mml:math id="M15"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> and low <mml:math id="M16"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math>. High <mml:math id="M17"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> increases alveolar dead space thus increasing the ventilatory requirement at a given metabolic rate and affecting the composition of mixed expired gas. Low <mml:math id="M18"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> results in a phenomenon called venous admixture or physiological shunt, whereby poorly oxygenated blood passes through the lungs and mixes with the blood draining into the left atrium, which will eventually be delivered to the systemic circulation via contraction of the left ventricle (<xref ref-type="bibr" rid="b4">4</xref>). The deficit in systemic arterial oxygen content (hypoxemia) which results from venous admixture worsens with increased blood flow through areas of low <mml:math id="M19"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> as can be seen with increases in cardiac output during exercise.</p><sec><title>Theoretical impact of venous admixture on arterial oxygenation</title><p>The impact of venous admixture on arterial oxygenation can be understood by considering the classical equation used to calculate physiological shunt:<disp-formula><mml:math id="M20"><mml:mrow><mml:msub><mml:mrow><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mtext>&#x000a0;&#x000b7;&#x000a0;</mml:mtext><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub><mml:mtext>&#x000a0;=&#x000a0;</mml:mtext><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mtext>&#x000a0;&#x000b7;&#x000a0;</mml:mtext><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mtext>&#x000a0;+&#x000a0;</mml:mtext><mml:msup><mml:mrow><mml:mi>C</mml:mi><mml:mi>p</mml:mi><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x02032;</mml:mo></mml:mrow></mml:msup><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mtext>&#x000a0;&#x000b7;&#x000a0;</mml:mtext><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mi>P</mml:mi></mml:msub></mml:mrow></mml:math></disp-formula>where <mml:math id="M21"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math> is total pulmonary blood flow, <mml:math id="M22"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math> is pulmonary shunt or venous admixture, <mml:math id="M23"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math> is the remainder of the pulmonary blood flow and <italic>Cpc&#x02032;O</italic><sub>2</sub> is the end-pulmonary capillary oxygen content.<disp-formula><mml:math id="M24"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mi>A</mml:mi><mml:mi>l</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>y</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:mi>O</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mtext>&#x000a0;&#x000b7;&#x000a0;</mml:mtext><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>C</mml:mi><mml:mi>p</mml:mi><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x02032;</mml:mo></mml:mrow></mml:msup><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mtext>&#x000a0;&#x000b7;&#x000a0;</mml:mtext><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>b</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>C</mml:mi><mml:mi>p</mml:mi><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x02032;</mml:mo></mml:mrow></mml:msup><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mtext>&#x000a0;&#x000b7;&#x000a0;</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>(</mml:mo><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msup><mml:mrow><mml:mi>C</mml:mi><mml:mi>p</mml:mi><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x02032;</mml:mo></mml:mrow></mml:msup><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>C</mml:mi><mml:mi>p</mml:mi><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x02032;</mml:mo></mml:mrow></mml:msup><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>This equation has been used in <xref ref-type="fig" rid="fig1">Figure 1a</xref> and <xref ref-type="fig" rid="fig1">1b</xref> to derive <italic>CaO</italic><sub>2</sub> for different values of <mml:math id="M25"><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math> and <mml:math id="M26"><mml:mrow><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math> assuming that <italic>Cpc&#x02032;O</italic><sub>2</sub> is 0.20 L/L. From these calculations one can deduce that for a pulmonary shunt fraction or venous admixture that equates to 20% of the cardiac output, <italic>CaO</italic><sub>2</sub> would decrease by 0.002 L/L (0.2 ml/dl) for a decrease in <mml:math id="M27"><mml:mrow><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math> of 0.01 L/L (1 ml/dl).</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Theoretical calculations based on the classical shunt equation: (a) Effect of venous admixture or pulmonary shunt fraction (<mml:math id="M28"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>) on arterial oxygen content (CaO<sub>2</sub>) for a given mixed venous oxygen content (<mml:math id="M29"><mml:mrow><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math>) assuming ideal pulmonary capillary oxygen content is 0.20 L/L; (b) effect of <mml:math id="M30"><mml:mrow><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math> on CaO<sub>2</sub> for a given <mml:math id="M31"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math> also assuming ideal pulmonary capillary oxygen content is 0.20 L/L; and (c) effect of an arteriovenous stula expressed as a fraction of cardiac output (<mml:math id="M32"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>) on <mml:math id="M33"><mml:mrow><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math> for a given CaO<sub>2</sub> assuming systemic capillary oxygen content is 0.15 L/L.</p></caption><graphic xlink:href="lcpd5-376-f1"/></fig></sec><sec><title>The role of oxygenation in exercise limitation</title><p>Exercise physiology is a complex subject but practical approaches have increased our understanding (<xref ref-type="bibr" rid="b5">5</xref>). With the performance of external work there is an obligatory requirement for energy to facilitate muscle contraction. Ideally, under aerobic conditions, when oxygen is in plentiful supply, increases in external work are match by increases in oxygen uptake. The presence of sufficient oxygen allows complete combustion of metabolic substrate with the generation or regeneration of ATP from oxidative phosphorylation. Hence, it is the contracting muscle that dictates the oxygen uptake required for the performance of exercise (<xref ref-type="bibr" rid="b6">6</xref>).</p><p>The circulation plays a role in transporting oxygen from the lungs to skeletal muscles and oxygen delivery to tissues can be calculated by the following formula:<disp-formula><mml:math id="M34"><mml:mrow><mml:mi>D</mml:mi><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:mtext>&#x000a0;</mml:mtext><mml:mn>&#x000b7;</mml:mn><mml:mtext>&#x000a0;</mml:mtext><mml:msub><mml:mrow><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula>where <italic>DO</italic><sub>2</sub> is oxygen delivery in L/min, <mml:math id="M35"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math> is cardiac output also in L/min and <italic>CaO</italic><sub>2</sub> is arterial oxygen content in liters of oxygen per liter of blood.</p><p>Given the simplicity of this formula it can be seen that <mml:math id="M36"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math> and <italic>CaO</italic><sub>2</sub> are equally important determinants of <italic>DO</italic><sub>2</sub>. Cardiac output would seem to be important in adjusting oxygen delivery during exercise. However, patients with mild to moderate chronic pulmonary disease do not have difficulty increasing <mml:math id="M37"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math> on exertion (<xref ref-type="bibr" rid="b7">7</xref>) and even patients with severe hyperinflation may have normal hemodynamics (<xref ref-type="bibr" rid="b8">8</xref>). On the other hand, patients with severe COPD associated with marked airflow obstruction, hyperinflation and increased work of breathing exhibit large swings in intrathoracic pressure during the breathing cycle that could adversely impact cardiac function (<xref ref-type="bibr" rid="b9">9</xref>). Despite these considerations, it seems likely that these patients will have greater difficulty maintaining arterial oxygen content than cardiac output.</p><p>The importance of <italic>CaO</italic><sub>2</sub> is not simply as a determinant of oxygen delivery by blood flow but also in maintaining an adequate oxygen diffusion gradient in the tissues. At rest, <italic>CaO</italic><sub>2</sub> is 0.20 L/L (20 ml/dl) compared with mixed venous oxygen content (<mml:math id="M38"><mml:mrow><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math>) that is 0.15 L/L (15 ml/dl). Hence, only about 25% of the oxygen available in arterial blood is extracted by the tissues. During exercise <italic>CaO</italic><sub>2</sub> does not normally change but <mml:math id="M39"><mml:mrow><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math> can fall as low as 0.05 L/L (5 ml/dl) reflecting increased oxygen extraction by exercising muscles. Interestingly, it is not simply the oxygen delivery that is important in providing oxygen to exercising muscle but the fact that a critical oxygen partial pressure can be sustained in the muscle capillaries. This critical capillary oxygen partial pressure (<italic>Pmc&#x02032;O</italic><sub>2</sub>) is the necessary driving pressure for oxygen diffusion from the muscle capillary to the mitochondrion. <italic>Pmc&#x02032;O</italic><sub>2</sub> is thought to be approximately 20 mm Hg whereas the mitochondrial oxygen partial pressure is only about 1 mm Hg (<xref ref-type="bibr" rid="b10">10</xref>). While the muscle capillary oxygen partial pressure is clearly influenced by oxygen delivery and oxygen utilization in the muscle, it is also crucially dependent on <italic>CaO</italic><sub>2</sub>. One can easily envisage a situation where <mml:math id="M40"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math> and muscle blood flow are increased but because of a low <italic>CaO</italic><sub>2</sub>, the <italic>Pc&#x02032;O</italic><sub>2</sub> cannot be maintained.</p><p>Let us then consider the pathologies that affect the provision of oxygen to skeletal muscle. Firstly, there is cardiac failure resulting in low <mml:math id="M41"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>. <italic>DO</italic><sub>2</sub> is reduced in direct proportion to the reduced <mml:math id="M42"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>; however, typically, in this setting, tissue oxygen extraction proceeds resulting in a lower <mml:math id="M43"><mml:mrow><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math>. Provided <italic>CaO</italic><sub>2</sub> is adequate, and <mml:math id="M44"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math> is not extremely low, it should still be possible to maintain the <italic>Pmc&#x02032; O</italic><sub>2</sub>.</p><p>Hemoglobin concentration is another factor which influences <italic>CaO</italic><sub>2</sub> because <italic>CaO</italic><sub>2</sub> is calculated as the sum of the oxygen combined with hemoglobin and that dissolved in the plasma.</p><p>The formula that determines <italic>CaO</italic><sub>2</sub> is as follows (<xref ref-type="bibr" rid="b11">11</xref>):<disp-formula><mml:math id="M45"><mml:mrow><mml:msub><mml:mrow><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo>[</mml:mo><mml:mi>H&#x000a0;</mml:mi><mml:mi>b</mml:mi><mml:mo>]</mml:mo><mml:mo>&#x000a0;&#x000b7;&#x000a0;</mml:mo><mml:mn>1</mml:mn><mml:mo>.</mml:mo><mml:mn>34</mml:mn><mml:mo>&#x000a0;&#x000b7;&#x000a0;</mml:mo><mml:msub><mml:mrow><mml:mi>S</mml:mi><mml:mi>a</mml:mi><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>P</mml:mi><mml:mi>a</mml:mi><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>&#x000a0;&#x000b7;&#x000a0;</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>0031</mml:mn></mml:mrow></mml:math></disp-formula>where <italic>CaO</italic><sub>2</sub> is arterial oxygen content in ml of oxygen per deciliter of blood, <italic>SaO</italic><sub>2</sub> is the percentage oxyhemoglobin saturation, [<italic>Hb</italic>] is hemoglobin concentration in g/dl, <italic>PaO</italic><sub>2</sub> is the arterial oxygen partial pressure in mm Hg.</p><p>This formula shows that in anemia, a reduction of hemoglobin concentration of 1 g/dl will result in approximate 6&#x02013;7% reduction in arterial oxygen content. The importance of this observation in patients with chronic pulmonary disease is unknown but many of these patients have anemia or relative anemia (<xref ref-type="bibr" rid="b12">12</xref>) and anemia adversely affects exercise capacity in COPD (<xref ref-type="bibr" rid="b13">13</xref>).</p><p>Venous admixture is arguably a much more serious consideration in terms of providing oxygen to skeletal muscle. To the extent that venous admixture lowers <italic>CaO</italic><sub>2</sub> it will also reduce the driving pressure for oxygen diffusion in the tissues and in these circumstances it might not be possible to maintain the <italic>Pmc&#x02032;O</italic><sub>2</sub>. Interestingly, in circumstances of skeletal muscle dysfunction where the muscle is unable to utilize oxygen because of structural or metabolic abnormalities, then <mml:math id="M46"><mml:mrow><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math> might actually be higher than normal (<xref ref-type="bibr" rid="b14">14</xref>).</p><p>Hence, the complex pathophysiology which occurs in chronic pulmonary diseases can impair exercise performance in several ways. Increased ventilatory requirement for a given level of exercise, causes dyspnea and, in some cases, ventilatory limitation (<xref ref-type="bibr" rid="b15">15</xref>). Hypoxemia reduces oxygen delivery to skeletal muscles as well as markedly worsening dyspnea through carotid body stimulation.</p></sec><sec><title>Approaches to improving exercise performance in chronic obstructive pulmonary disease</title><p>Chronic obstructive pulmonary disease (COPD) is a progressive disease that encompasses chronic bronchitis and emphysema (<xref ref-type="bibr" rid="b16">16</xref>). COPD is the most common chronic pulmonary disease worldwide and is thought to affect 24 million Americans (<xref ref-type="bibr" rid="b17">17</xref>). About 2&#x02013;3 million of these are likely to have severe disease with significant hypoxemia and exercise impairment. The mechanisms of exercise limitation described above are highly relevant to patients with severe COPD. They have reduced aerobic capacity, deconditioning, increased ventilatory requirement and chronic hypoxemia that predictably worsens with exertion (<xref ref-type="bibr" rid="b18">18</xref>). When these patients reach this stage of disease severity their therapeutic options are limited. Nevertheless, there has been considerable progress in recent years in developing approaches to improve exercise performance in patients with chronic pulmonary diseases, particularly in COPD (<xref ref-type="bibr" rid="b19">19</xref>).</p><p>Inhaled bronchodilator therapy is regarded as important in the maintenance treatment of COPD because of the demonstrated benefits on dyspnea, exercise performance and quality of life. Studies of long-acting bronchodilators indicate that these benefits relate to reduced static and dynamic hyperinflation (<xref ref-type="bibr" rid="b20">20</xref>&#x02013;<xref ref-type="bibr" rid="b22">22</xref>). Phenotypically, therefore, the type of patient who benefits from bronchodilator therapy, at least in terms of reducing lung volume, has emphysematous destruction of the lung parenchyma and a component of high <mml:math id="M47"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> abnormality.</p><p>Even in patients with severe chronic pulmonary diseases, physical reconditioning can be achieved through structured exercise training programs (<xref ref-type="bibr" rid="b23">23</xref>). These programs reduce lactic acid accumulation and hence reduce ventilatory requirement for a given level of exercise (<xref ref-type="bibr" rid="b24">24</xref>). They also improve breathing efficiency, regardless of the reconditioning effect and this benefit probably relates to slowed breathing frequency (<xref ref-type="bibr" rid="b25">25</xref>).</p><p>Patients who demonstrate hypoxemia during exercise show improved exercise performance with supplemental oxygen (<xref ref-type="bibr" rid="b26">26</xref>). An obvious mechanism for this benefit would be correction of the hypoxemia but a secondary improvement in breathing mechanics might also occur due to reduced breathing frequency from suppression of carotid body activity (<xref ref-type="bibr" rid="b27">27</xref>).</p><p>Supplemental oxygen is considered effective at correcting the hypoxemia that results from <mml:math id="M48"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> mismatch in the lungs. The rationale is shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Effect of supplemental oxygen on ventilation-perfusion mismatch (low <mml:math id="M49"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math>) and intra-pulmonary shunt (<mml:math id="M50"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math>). When breathing 100% oxygen from a closed circuit (FIO<sub>2</sub> 100%), even lung regions with very low alveolar ventilation (on the left) should see an increase in alveolar oxygen tension (PAO2) to greater then 100 mm Hg in which case the blood draining that region will be fully saturated. By contrast, regions of intra-pulmonary shunt (on the right) experience no ventilation and the blood draining those regions has an oxygen content equal to the mixed venous blood (<mml:math id="M51"><mml:mrow><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math>).</p></caption><graphic xlink:href="lcpd5-376-f2"/></fig><p>By substantially increasing the inspired oxygen concentration and partial pressure, it is believed that even areas of low <mml:math id="M52"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> that have low levels of ventilation will experience a sufficient increase in alveolar oxygen partial pressure (&#x0003e; 100 mm Hg) to fully oxygenate the blood in the adjacent pulmonary capillaries. This will reduce but not abolish venous admixture because areas with no ventilation (<mml:math id="M53"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math>) will not be influenced by the inspired oxygen concentration.</p><p>To the extent that a patient with chronic pulmonary disease has increased physiological shunt, that patient will be refractory to the benefits from supplemental oxygen. These pathophysio-logical effects are seen in many types of lung disease but particularly in patients with COPD (<xref ref-type="bibr" rid="b18">18</xref>) and pulmonary fibrosis (<xref ref-type="bibr" rid="b28">28</xref>).</p></sec><sec><title>Mechanisms to reduce the adverse consequences of venous admixture</title><p>Venous admixture becomes extremely relevant as a cause of hypoxemia in patients with chronic pulmonary diseases, particularly during exercise when cardiac output is increased and flow through areas of intra-pulmonary shunt is increased. Furthermore, as noted above, supplemental oxygen only benefits areas of <mml:math id="M54"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> mismatch and patients with extensive intra-pulmonary shunt may actually be refractory to this treatment. Elevation of <mml:math id="M55"><mml:mrow><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math> should ameliorate the deleterious effects of venous admixture both at rest and also, importantly during exercise. In therapeutic terms there are few ways to increase <mml:math id="M56"><mml:mrow><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math>.</p><p>One simple method would be to increase [<italic>Hb</italic>] by blood transfusion or stimulation of erythropoesis. Autotransfusion of blood in athletes (blood doping) is well know to enhance aerobic performance although in the context of an athlete the mechanisms are probably somewhat different (<xref ref-type="bibr" rid="b29">29</xref>). Improved exercise performance related to increased red cell mass can also achieved in athletes by stimulation of erythropoesis with hypobaric hypoxia (altitude) (<xref ref-type="bibr" rid="b30">30</xref>). Human erythropoietin or its analogues have been considered but concerns exist as to what is an appropriate [<italic>Hb</italic>] in a patient with chronic hypoxemia and what is the risk of intravascular thrombosis due to increased blood viscosity (<xref ref-type="bibr" rid="b31">31</xref>). The cost of these agents is also likely to be a limiting factor.</p><p>A more intriguing method by which to increase <mml:math id="M57"><mml:mrow><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math> is the therapeutic creation of an arterio-venous (AV) fistula. This approach would shunt oxygenated arterial blood from the systemic arterial circulation to the systemic veins thus directly influencing and increasing <mml:math id="M58"><mml:mrow><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math>. There has been extensive previous experience of artificially created AV fistulae in the context of renal failure patients needing hemodialysis (<xref ref-type="bibr" rid="b32">32</xref>). A theoretical advantage of the therapeutic AV fistula is that it should improve hypoxemia not only in patients with <mml:math id="M59"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> mismatch but also those with increased physiological shunt who are refractory to treatment with supplemental oxygen.</p><p>The effect of an arteriovenous fistula on <mml:math id="M60"><mml:mrow><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math> can be explored theoretically with an equation analogous to that used for the calculation of <italic>CaO</italic><sub>2</sub> taking into account physiological shunt:<disp-formula><mml:math id="M61"><mml:mrow><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>&#x000a0;&#x000b7;&#x000a0;</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>&#x000a0;&#x000b7;&#x000a0;</mml:mo><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>C</mml:mi><mml:mi>s</mml:mi><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x02032;</mml:mo></mml:mrow></mml:msup><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>&#x000a0;&#x000b7;&#x000a0;</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula>where <mml:math id="M62"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math> is total systemic blood flow, <mml:math id="M63"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math> is the blood flow through the fistula, <mml:math id="M64"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math> is the remainder of the systemic blood flow and <italic>Csc&#x02032;O</italic><sub>2</sub> is the mixed systemic capillary oxygen content.<disp-formula><mml:math id="M65"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mi>A</mml:mi><mml:mi>l</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>y</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>&#x000a0;&#x000b7;&#x000a0;</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>C</mml:mi><mml:mi>s</mml:mi><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x02032;</mml:mo></mml:mrow></mml:msup><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>&#x000a0;&#x000b7;&#x000a0;</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>b</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>&#x000a0;&#x000b7;&#x000a0;</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>C</mml:mi><mml:mi>s</mml:mi><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x02032;</mml:mo></mml:mrow></mml:msup><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>&#x000a0;&#x000b7;&#x000a0;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msup><mml:mrow><mml:mi>C</mml:mi><mml:mi>s</mml:mi><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x02032;</mml:mo></mml:mrow></mml:msup><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>C</mml:mi><mml:mi>s</mml:mi><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x02032;</mml:mo></mml:mrow></mml:msup><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>This equation has been used in <xref ref-type="fig" rid="fig1">Figure 1c</xref> to derive <mml:math id="M66"><mml:mrow><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math> for different values of <mml:math id="M67"><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math> and <italic>CaO</italic><sub>2</sub> assuming that <italic>Csc&#x02032;O</italic><sub>2</sub> is 0.15 L/L. From these calculations one can deduce that for a <italic>CaO</italic><sub>2</sub> of 0.18 L/L (18 ml/dl or &#x02248;90% saturation), an increase in flow through the fistula of 0.1 (10% of total systemic blood flow) would increase <mml:math id="M68"><mml:mrow><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math> by 0.003 L/L (0.3 ml/dL).</p><p>Any COPD patient with hypoxemia, either chronically at rest or intermittently during exercise, would be expected to have a range of low <mml:math id="M69"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> abnormalities in the lungs. In these patients, the component of &#x0201c;<mml:math id="M70"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> mismatch&#x0201d; or low <mml:math id="M71"><mml:mrow><mml:mover><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover><mml:mo>/</mml:mo><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow></mml:math> would be expected to improve, at least to some extent, with supplemental oxygen. The same patients would most likely have a degree of venous admixture which would be refractory to supplemental oxygen but could potentially be improved by creation of an arterio-venous fistula that elevates <mml:math id="M72"><mml:mrow><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math>.</p></sec><sec><title>Potential adverse consequences of an arterio-venous fistula</title><p>Peripheral arterio-venous fistulae or shunts represent a reduction in systemic vascular resistance and therefore tend to be associated with an increased cardiac output. The question obviously arises as to how this would be tolerated over time. Furthermore, patients with chronic pulmonary disease might already be experiencing right ventricular compromise from increased afterload due to hypoxic pulmonary vasoconstriction or pulmonary vascular remodeling. An increased <mml:math id="M73"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math> could worsen this situation and lead to further increases in pulmonary arterial pressures. On the other hand, if the elevation of <mml:math id="M74"><mml:mrow><mml:mi>C</mml:mi><mml:mover><mml:mrow><mml:mi>&#x003c5;</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x000af;</mml:mo></mml:mrow></mml:mover><mml:msub><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math> contributed to an improvement of oxygenation within the lung there could be a reduction in hypoxic pulmonary vasoconstriction, reduction in pulmonary vascular resistance and paradoxical reduction in pulmonary arterial pressures despite the increased <mml:math id="M75"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>. Preliminary data from patients with severe COPD suggest that these effects can occur (<xref ref-type="bibr" rid="b33">33</xref>).</p><p>Another concern would be that creation of an AV fistula would divert some of the arterial blood flow to that limb resulting in a relative deprivation of oxygen delivery. Whilst theoretically possible, it is also likely that local autoregulation would preserve the arterial blood flow distal to the fistula and that the increased <mml:math id="M76"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x002d9;</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math> is in part a reflection of this adaptation.</p></sec></sec><sec><title>SUMMARY</title><p>Patients with chronic pulmonary disease that have disrupted gas exchange which increases physiological shunt and venous admixture. These patients have serious problems with oxygenation and are often somewhat refractory to treatment with supplemental oxygen particularly during exercise. Theoretically they could benefit from an intervention that increased mixed venous oxygen content thereby ameliorating the deleterious effects of venous admixture.</p><p>One such intervention that warrants further investigation is the therapeutic creation of an arterio-venous fistula. Such an approach would be novel, simple and minimally invasive. There is reason to believe that complications would be minor leading to a favorable risk-benefit analysis. This approach to treatment could have significant impact for patients with COPD but should also benefit any patient with chronic hypoxemia that impairs exercise performance.</p></sec></body><back><ref-list><title>References</title><ref id="b1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>CB</given-names></name></person-group><article-title>Determining the role of exercise in patients with chronic pulmonary disease</article-title><source>Med Sci Sports Exerc</source><year>1995</year><volume>27</volume><fpage>147</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">7723635</pub-id></citation></ref><ref id="b2"><label>2</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Astrand</surname><given-names>P-O</given-names></name><name><surname>Rodahl</surname><given-names>K</given-names></name></person-group><source>Textbook of work physiology</source><year>1970</year><publisher-name>McGraw-Hill</publisher-name></citation></ref><ref id="b3"><label>3</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>West</surname><given-names>JB</given-names></name></person-group><source>Ventilation/blood o w and gas exchange</source><year>1985</year><edition>4th ed</edition><publisher-loc>Oxford</publisher-loc><publisher-name>Blackwell Scienti c Publications</publisher-name></citation></ref><ref id="b4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>PD</given-names></name></person-group><article-title>Ventilation/perfusion relationships</article-title><source>Clin Physiol</source><year>1981</year><volume>1</volume><fpage>437</fpage><lpage>451</lpage><pub-id pub-id-type="pmid">6802555</pub-id></citation></ref><ref id="b5"><label>5</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>CB</given-names></name><name><surname>Storer</surname><given-names>TW</given-names></name></person-group><source>Exercise Testing and Interpretation: A Practical Approach</source><year>2001</year><publisher-loc>New York</publisher-loc><publisher-name>Cambridge University Press</publisher-name></citation></ref><ref id="b6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>PD</given-names></name></person-group><article-title>New ideas on limitations to VO<sub>2</sub>max</article-title><source>Exerc Sport Sci Rev</source><year>2000</year><volume>28</volume><fpage>10</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">11131681</pub-id></citation></ref><ref id="b7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spiro</surname><given-names>SG</given-names></name><name><surname>Hahn</surname><given-names>HL</given-names></name><name><surname>Edwards</surname><given-names>RH</given-names></name><etal/></person-group><article-title>An analysis of the physiological strain of submaximal exercise in patients with chronic obstructive bronchitis</article-title><source>Thorax</source><year>1975</year><volume>30</volume><fpage>415</fpage><lpage>425</lpage><pub-id pub-id-type="pmid">1179325</pub-id></citation></ref><ref id="b8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marchetti</surname><given-names>N</given-names></name><name><surname>Panetta</surname><given-names>N</given-names></name><name><surname>Criner</surname><given-names>G</given-names></name></person-group><article-title>The effect of lung hyperin ation in COPD on cardiac function</article-title><source>Proc Am Thorac Soc</source><year>2008</year><volume>177</volume><fpage>A782</fpage></citation></ref><ref id="b9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Montes de Oca</surname><given-names>M</given-names></name><name><surname>Rassulo</surname><given-names>J</given-names></name><name><surname>Celli</surname><given-names>BR</given-names></name></person-group><article-title>Respiratory muscle and cardiopulmonary function during exercise in very severe COPD</article-title><source>Am J Respir Crit Care Med</source><year>1996</year><volume>154</volume><fpage>1284</fpage><lpage>1289</lpage><pub-id pub-id-type="pmid">8912737</pub-id></citation></ref><ref id="b10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>PD</given-names></name></person-group><article-title>Diffusive resistance to O<sub>2</sub> transport in muscle</article-title><source>Acta Physiol Scand</source><year>2000</year><volume>168</volume><fpage>609</fpage><lpage>614</lpage><pub-id pub-id-type="pmid">10759597</pub-id></citation></ref><ref id="b11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Severinghaus</surname><given-names>JW</given-names></name></person-group><article-title>Simple, accurate equations for human blood O2 dissociation computations</article-title><source>J Appl Physiol</source><year>1979</year><volume>46</volume><fpage>599</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">35496</pub-id></citation></ref><ref id="b12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>John</surname><given-names>M</given-names></name><name><surname>Lange</surname><given-names>A</given-names></name><name><surname>Hoernig</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prevalence of anemia in chronic obstructive pulmonary disease: comparison to other chronic diseases</article-title><source>Int J Cardiol</source><year>2006</year><volume>111</volume><fpage>365</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">16242192</pub-id></citation></ref><ref id="b13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cote</surname><given-names>C</given-names></name><name><surname>Zilberberg</surname><given-names>MD</given-names></name><name><surname>Mody</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Haemoglobin level and its clinical impact in a cohort of patients with COPD</article-title><source>Eur Respir J</source><year>2007</year><volume>29</volume><fpage>923</fpage><lpage>929</lpage><pub-id pub-id-type="pmid">17251227</pub-id></citation></ref><ref id="b14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>GE</given-names></name><name><surname>Parsons</surname><given-names>DB</given-names></name><name><surname>Stray-Gundersen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Uremic myopathy limits aerobic capacity in hemodialysis patients</article-title><source>Am J Kidney Dis</source><year>1993</year><volume>22</volume><fpage>277</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">8352254</pub-id></citation></ref><ref id="b15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>CB</given-names></name></person-group><article-title>Exercise in chronic pulmonary disease: aerobic exercise prescription</article-title><source>Med Sci Sports Exerc</source><year>2001</year><volume>33</volume><fpage>S671</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">11462076</pub-id></citation></ref><ref id="b16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fabbri</surname><given-names>L</given-names></name><name><surname>Pauwels</surname><given-names>RA</given-names></name><name><surname>Hurd</surname><given-names>SS</given-names></name></person-group><article-title>Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary updated 2003</article-title><source>COPD</source><year>2004</year><volume>1</volume><fpage>105</fpage><lpage>141</lpage><comment>discussion 103&#x02014;104</comment><pub-id pub-id-type="pmid">16997745</pub-id></citation></ref><ref id="b17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mannino</surname><given-names>DM</given-names></name><name><surname>Homa</surname><given-names>DM</given-names></name><name><surname>Akinbami</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Chronic obstructive pulmonary disease surveillance United States, 1971&#x02014;2000</article-title><source>MMWR Surveill Summ</source><year>2002</year><volume>51</volume><fpage>1</fpage><lpage>16</lpage></citation></ref><ref id="b18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>CB</given-names></name></person-group><article-title>The connection between chronic obstructive pulmonary disease symptoms and hyperin ation and its impact on exercise and function</article-title><source>Am J Med</source><year>2006</year><volume>119</volume><fpage>21</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">16996896</pub-id></citation></ref><ref id="b19"><label>19</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Casaburi</surname><given-names>R</given-names></name><name><surname>Petty</surname><given-names>TL</given-names></name></person-group><source>Principles and practice of pulmonary rehabilitation</source><year>1993</year><publisher-loc>Philadelphia</publisher-loc><publisher-name>WB Saunders Company</publisher-name></citation></ref><ref id="b20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Celli</surname><given-names>B</given-names></name><name><surname>ZuWallack</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Improvement in resting inspiratory capacity and hyperin ation with tiotropium in COPD patients with increased static lung volumes</article-title><source>Chest</source><year>2003</year><volume>124</volume><fpage>1743</fpage><lpage>1748</lpage><pub-id pub-id-type="pmid">14605043</pub-id></citation></ref><ref id="b21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Donnell</surname><given-names>DE</given-names></name><name><surname>Fluge</surname><given-names>T</given-names></name><name><surname>Gerken</surname><given-names>F</given-names></name><etal/></person-group><article-title>Effects of tiotropium on lung hyperin ation, dyspnoea and exercise tolerance in COPD</article-title><source>Eur Respir J</source><year>2004</year><volume>23</volume><fpage>832</fpage><lpage>840</lpage><pub-id pub-id-type="pmid">15218994</pub-id></citation></ref><ref id="b22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Donnell</surname><given-names>DE</given-names></name><name><surname>Voduc</surname><given-names>N</given-names></name><name><surname>Fitzpatrick</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease</article-title><source>Eur Respir J</source><year>2004</year><volume>24</volume><fpage>86</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">15293609</pub-id></citation></ref><ref id="b23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nici</surname><given-names>L</given-names></name><name><surname>Donner</surname><given-names>C</given-names></name><name><surname>Wouters</surname><given-names>E</given-names></name><etal/></person-group><article-title>American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation</article-title><source>Am J Respir Crit Care Med</source><year>2006</year><volume>173</volume><fpage>1390</fpage><lpage>1413</lpage><pub-id pub-id-type="pmid">16760357</pub-id></citation></ref><ref id="b24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Casaburi</surname><given-names>R</given-names></name><name><surname>Patessio</surname><given-names>A</given-names></name><name><surname>Ioli</surname><given-names>F</given-names></name><etal/></person-group><article-title>Reductions in exercise lactic acidosis and ventilation as a result of exercise training in patients with obstructive lung disease</article-title><source>Am Rev Respir Dis</source><year>1991</year><volume>143</volume><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">1986689</pub-id></citation></ref><ref id="b25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Casaburi</surname><given-names>R</given-names></name><name><surname>Porszasz</surname><given-names>J</given-names></name><name><surname>Burns</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Physiologic benets of exercise training in rehabilitation of patients with severe chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>1997</year><volume>155</volume><fpage>1541</fpage><lpage>1551</lpage><pub-id pub-id-type="pmid">9154855</pub-id></citation></ref><ref id="b26"><label>26</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>CB</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Casaburi</surname><given-names>R</given-names></name><name><surname>Petty</surname><given-names>TL</given-names></name></person-group><article-title>Long-term oxygen therapy</article-title><source>Principles and practice of pulmonary rehabilitation</source><year>1993</year><publisher-loc>Philadelphia</publisher-loc><publisher-name>WB Saunders Company</publisher-name></citation></ref><ref id="b27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Emtner</surname><given-names>M</given-names></name><name><surname>Porszasz</surname><given-names>J</given-names></name><name><surname>Burns</surname><given-names>M</given-names></name><etal/></person-group><article-title>Bene ts of supplemental oxygen in exercise training in nonhypoxemic chronic obstructive pulmonary disease patients</article-title><source>Am J Respir Crit Care Med</source><year>2003</year><volume>168</volume><fpage>1034</fpage><lpage>1042</lpage><pub-id pub-id-type="pmid">12869359</pub-id></citation></ref><ref id="b28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Markovitz</surname><given-names>GH</given-names></name><name><surname>Cooper</surname><given-names>CB</given-names></name></person-group><article-title>Exercise and interstitial lung disease</article-title><source>Curr Opin Pulm Med</source><year>1998</year><volume>4</volume><fpage>272</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">10813202</pub-id></citation></ref><ref id="b29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ekblom</surname><given-names>BT</given-names></name></person-group><article-title>Blood boosting and sport</article-title><source>Baillieres Best Pract Res Clin Endocrinol Metab</source><year>2000</year><volume>14</volume><fpage>89</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">10932813</pub-id></citation></ref><ref id="b30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>BD</given-names></name><name><surname>Stray-Gundersen</surname><given-names>J</given-names></name></person-group><article-title>Living high-training low&#x0201d;: effect of moderate-altitude acclimatization with low-altitude training on performance</article-title><source>J Appl Physiol</source><year>1997</year><volume>83</volume><fpage>102</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">9216951</pub-id></citation></ref><ref id="b31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaudard</surname><given-names>A</given-names></name><name><surname>Varlet-Marie</surname><given-names>E</given-names></name><name><surname>Bressolle</surname><given-names>F</given-names></name><etal/></person-group><article-title>Drugs for increasing oxygen and their potential use in doping: a review</article-title><source>Sports Med</source><year>2003</year><volume>33</volume><fpage>187</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">12656640</pub-id></citation></ref><ref id="b32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brittinger</surname><given-names>WD</given-names></name><name><surname>Twittenhoff</surname><given-names>WD</given-names></name><name><surname>Schwarzbeck</surname><given-names>A</given-names></name><etal/></person-group><article-title>Haemodynamic effects of A-V shunts and their clinical signi cance</article-title><source>Proc Eur Dial Transplant Assoc</source><year>1972</year><volume>9</volume><fpage>642</fpage><lpage>649</lpage><pub-id pub-id-type="pmid">4668949</pub-id></citation></ref><ref id="b33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Galindo</surname><given-names>J</given-names></name><name><surname>Posadas</surname><given-names>R</given-names></name><etal/></person-group><article-title>Improved exercise performance with supplemental oxygen predicts a bene cial response to therapeutic arterio-venous stula in patients with severe COPD</article-title><source>Chest</source><year>2007</year><volume>132</volume><fpage>453S</fpage></citation></ref></ref-list></back></article>